TISIDB

Summary
Symbol	KCNJ10
Name	potassium channel, inwardly rectifying subfamily J, member 10
Aliases	Kir4.1; Kir1.2; potassium inwardly-rectifying channel, subfamily J, member 10; BIRK-10; KCNJ13-PEN; SESAME; ......
Chromosomal Location	1q23.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Membrane Multi-pass membrane protein. Basolateral cell membrane Note=In kidney distal convoluted tubules, located in the basolateral membrane where it colocalizes with KCNJ16.
Domain	PF01007 Inward rectifier potassium channel
Function	May be responsible for potassium buffering action of glial cells in the brain. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. Can be blocked by extracellular barium and cesium (By similarity). In the kidney, together with KCNJ16, mediates basolateral K(+) recycling in distal tubules; this process is critical for Na(+) reabsorption at the tubules.

> Gene Ontology [ TOP ]
Biological Process	GO:0001504 neurotransmitter uptake GO:0001505 regulation of neurotransmitter levels GO:0006813 potassium ion transport GO:0006820 anion transport GO:0006836 neurotransmitter transport GO:0006865 amino acid transport GO:0007272 ensheathment of neurons GO:0007601 visual perception GO:0007626 locomotory behavior GO:0007628 adult walking behavior GO:0008344 adult locomotory behavior GO:0008366 axon ensheathment GO:0010001 glial cell differentiation GO:0010107 potassium ion import GO:0014003 oligodendrocyte development GO:0015672 monovalent inorganic cation transport GO:0015711 organic anion transport GO:0015849 organic acid transport GO:0021782 glial cell development GO:0022010 central nervous system myelination GO:0030534 adult behavior GO:0032291 axon ensheathment in central nervous system GO:0034762 regulation of transmembrane transport GO:0034765 regulation of ion transmembrane transport GO:0042063 gliogenesis GO:0042391 regulation of membrane potential GO:0042552 myelination GO:0043090 amino acid import GO:0044708 single-organism behavior GO:0046942 carboxylic acid transport GO:0048167 regulation of synaptic plasticity GO:0048168 regulation of neuronal synaptic plasticity GO:0048169 regulation of long-term neuronal synaptic plasticity GO:0048709 oligodendrocyte differentiation GO:0050804 modulation of synaptic transmission GO:0050953 sensory perception of light stimulus GO:0051933 amino acid neurotransmitter reuptake GO:0051935 glutamate reuptake GO:0051938 L-glutamate import GO:0055067 monovalent inorganic cation homeostasis GO:0055075 potassium ion homeostasis GO:0060075 regulation of resting membrane potential GO:0071804 cellular potassium ion transport GO:0071805 potassium ion transmembrane transport GO:0090659 walking behavior GO:0098657 import into cell GO:0098810 neurotransmitter reuptake GO:1902837 amino acid import into cell GO:1903802 L-glutamate(1-) import into cell
Molecular Function	GO:0005216 ion channel activity GO:0005242 inward rectifier potassium channel activity GO:0005244 voltage-gated ion channel activity GO:0005249 voltage-gated potassium channel activity GO:0005261 cation channel activity GO:0005267 potassium channel activity GO:0015077 monovalent inorganic cation transmembrane transporter activity GO:0015079 potassium ion transmembrane transporter activity GO:0015267 channel activity GO:0015272 ATP-activated inward rectifier potassium channel activity GO:0015276 ligand-gated ion channel activity GO:0015467 G-protein activated inward rectifier potassium channel activity GO:0022803 passive transmembrane transporter activity GO:0022832 voltage-gated channel activity GO:0022834 ligand-gated channel activity GO:0022836 gated channel activity GO:0022838 substrate-specific channel activity GO:0022843 voltage-gated cation channel activity GO:0046873 metal ion transmembrane transporter activity
Cellular Component	GO:0016323 basolateral plasma membrane GO:0098793 presynapse

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04971 Gastric acid secretion
Reactome	R-HSA-1296041: Activation of G protein gated Potassium channels R-HSA-991365: Activation of GABAB receptors R-HSA-1296059: G protein gated Potassium channels R-HSA-977444: GABA B receptor activation R-HSA-977443: GABA receptor activation R-HSA-997272: Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits R-HSA-1296065: Inwardly rectifying K+ channels R-HSA-112316: Neuronal System R-HSA-112314: Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell R-HSA-1296071: Potassium Channels R-HSA-1296067: Potassium transport channels R-HSA-112315: Transmission across Chemical Synapses

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04971 Gastric acid secretion

Reactome

R-HSA-1296041: Activation of G protein gated Potassium channels
R-HSA-991365: Activation of GABAB receptors
R-HSA-1296059: G protein gated Potassium channels
R-HSA-977444: GABA B receptor activation
R-HSA-977443: GABA receptor activation
R-HSA-997272: Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits
R-HSA-1296065: Inwardly rectifying K+ channels
R-HSA-112316: Neuronal System
R-HSA-112314: Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
R-HSA-1296071: Potassium Channels
R-HSA-1296067: Potassium transport channels
R-HSA-112315: Transmission across Chemical Synapses

Summary
Symbol	KCNJ10
Name	potassium channel, inwardly rectifying subfamily J, member 10
Aliases	Kir4.1; Kir1.2; potassium inwardly-rectifying channel, subfamily J, member 10; BIRK-10; KCNJ13-PEN; SESAME; ......
Chromosomal Location	1q23.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between KCNJ10 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	KCNJ10
Name	potassium channel, inwardly rectifying subfamily J, member 10
Aliases	Kir4.1; Kir1.2; potassium inwardly-rectifying channel, subfamily J, member 10; BIRK-10; KCNJ13-PEN; SESAME; ......
Chromosomal Location	1q23.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of KCNJ10 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	KCNJ10
Name	potassium channel, inwardly rectifying subfamily J, member 10
Aliases	Kir4.1; Kir1.2; potassium inwardly-rectifying channel, subfamily J, member 10; BIRK-10; KCNJ13-PEN; SESAME; ......
Chromosomal Location	1q23.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of KCNJ10 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.329	0.542
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.592	0.543
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.148	0.845
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.535	0.235
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.565	0.583
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.492	0.67
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	1.08	0.197
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	1.21	0.381
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	1.078	0.442
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.246	0.767
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.114	0.917
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	1.019	0.00139

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of KCNJ10 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	1.4	-1.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	1.7	-1.7	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	5.9	-5.9	0.447
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	9.1	-9.1	0.458
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	3.7	1.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	7.7	-3.2	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	KCNJ10
Name	potassium channel, inwardly rectifying subfamily J, member 10
Aliases	Kir4.1; Kir1.2; potassium inwardly-rectifying channel, subfamily J, member 10; BIRK-10; KCNJ13-PEN; SESAME; ......
Chromosomal Location	1q23.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of KCNJ10. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	KCNJ10
Name	potassium channel, inwardly rectifying subfamily J, member 10
Aliases	Kir4.1; Kir1.2; potassium inwardly-rectifying channel, subfamily J, member 10; BIRK-10; KCNJ13-PEN; SESAME; ......
Chromosomal Location	1q23.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of KCNJ10. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by KCNJ10. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	KCNJ10
Name	potassium channel, inwardly rectifying subfamily J, member 10
Aliases	Kir4.1; Kir1.2; potassium inwardly-rectifying channel, subfamily J, member 10; BIRK-10; KCNJ13-PEN; SESAME; ......
Chromosomal Location	1q23.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of KCNJ10. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	KCNJ10
Name	potassium channel, inwardly rectifying subfamily J, member 10
Aliases	Kir4.1; Kir1.2; potassium inwardly-rectifying channel, subfamily J, member 10; BIRK-10; KCNJ13-PEN; SESAME; ......
Chromosomal Location	1q23.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of KCNJ10 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	KCNJ10
Name	potassium channel, inwardly rectifying subfamily J, member 10
Aliases	Kir4.1; Kir1.2; potassium inwardly-rectifying channel, subfamily J, member 10; BIRK-10; KCNJ13-PEN; SESAME; ......
Chromosomal Location	1q23.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between KCNJ10 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	KCNJ10
Name	potassium channel, inwardly rectifying subfamily J, member 10
Aliases	Kir4.1; Kir1.2; potassium inwardly-rectifying channel, subfamily J, member 10; BIRK-10; KCNJ13-PEN; SESAME; ......
Chromosomal Location	1q23.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting KCNJ10 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting KCNJ10.

ID	Name	Drug Type	Targets	#Targets
DB01392	Yohimbine	Small Molecule	ADRA2A, ADRA2B, ADRA2C, DRD2, DRD3, HTR1A, HTR1B, HTR1D, HTR2A, HT ......	18

Browse KCNJ10